MHRA Updates Pharmacovigilance Guidance, Reinforcing Post-Market Surveillance for UK MAHs
The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its pharmacovigilance guidance, notably confirming a 21 August 2026 revision for EURD list details, and previously adding stringent requirements for signal detection, Risk Management Plans (RMPs), and Post Authorisation Safety Studies (PASS) submissions. These changes mandate increased post-market vigilance, particularly impacting manufacturers with Northern Ireland market access.
London, United Kingdom — 22 June 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has revised its pharmacovigilance guidance, with the latest significant update scheduled for 21 August 2026, focusing on the European Union Reference Date (EURD) list details under section 5.2. This follows a series of substantial updates, most notably on 28 October 2022, which introduced heightened submission requirements for Marketing Authorisation Holders (MAHs) operating within the UK market. The revisions underscore the MHRA's commitment to robust post-market surveillance and risk management for authorised medicinal products, including those with borderline classifications or those that have previously fallen under less stringent oversight.
The October 2022 amendments tightened protocols for signals, Risk Management Plans (RMPs), and Post Authorisation Safety Studies (PASS) submissions. This demands more rigorous data collection, analysis, and reporting from MAHs. Furthermore, the guidance introduced new requirements for Periodic Safety Update Reports (PSURs) specifically for products authorised in Northern Ireland, necessitating a dual-compliance strategy for businesses operating across Great Britain and Northern Ireland due to the Windsor Framework. These updates extend beyond traditional pharmaceuticals, often encompassing certain high-potency or novel ingredient supplements that cross regulatory boundaries, requiring diligent pharmacovigilance oversight.
Earlier revisions, such as the 14 October 2021 update, clarified submission and documentation requirements for various pharmacovigilance procedures, including reliance procedures. This provided a clearer framework for manufacturers leveraging existing authorisations or data. The MHRA has also published guidance and webinars related to the Windsor Framework, highlighting the persistent regulatory divergence post-Brexit and its implications for product distribution and safety monitoring within the UK internal market.
What this means for United Kingdom
UK-based manufacturers and brand owners must allocate increased resources to pharmacovigilance teams, especially for products with a Northern Ireland presence, to meet dual PSUR submission requirements by the October 2022 deadline implementation. The enhanced data submission for signals, RMPs, and PASS will directly impact operational costs and requires significant internal process reformulation. Compliance failure risks product delisting or regulatory sanctions, impacting market access and brand reputation. Proactive engagement with the 21 August 2026 EURD list update is crucial for optimising future PSUR planning and maintaining competitive advantage through streamlined regulatory operations.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.